Probiotics for Elderly Constipation: What the Trials Show

For an older adult with functional constipation, a Bifidobacterium animalis subsp. lactis probiotic is a reasonable adjunct to discuss with a clinician. It is not a replacement for polyethylene glycol (PEG/macrogol), the established first-line option with a longer safety record in older patients. The evidence has become more interesting, but it has not become simple.

A 2024 network meta-analysis placed fecal microbiota transplantation (FMT) at the top for several constipation outcomes. Meanwhile, several randomized trials have reported improved constipation outcomes with different B. lactis strains, including trials in older adults. Those findings justify attention. They do not justify telling a frail 78-year-old to abandon a treatment that works and start shopping for a stool donor. Medicine has enough unpleasant errands already.

FMT led a broad comparison, but that does not make it the practical choice

Tan et al.'s 2024 network meta-analysis analyzed 45 randomized controlled trials involving 17,118 people with chronic functional constipation. It compared chemical drugs, FMT, probiotics, dietary fiber, and acupuncture. FMT ranked highest for clinical efficacy, improvement in Bristol Stool Form Scale scores, and constipation-related quality of life.

That result matters because network meta-analysis can compare treatments that few, if any, trials have tested head to head. Still, ranking is not a treatment order. The available abstract does not report the exact SUCRA probabilities for each intervention class, and it does not separate probiotic results by genus, species, or strain. It also provides no elderly-specific subgroup analysis. A ranking built largely from indirect comparisons cannot tell us whether FMT is safer or more effective for older adults with frailty, immunosuppression, multiple medications, or other common clinical complications.

Within the chemical-drug subgroup, sodium picosulfate 10 mg ranked highest for clinical efficacy. Across all intervention classes, electroacupuncture had the lowest adverse-event incidence. Neither finding establishes that sodium picosulfate is the best long-term option for an elderly patient, or that probiotics beat PEG on safety. Those are different questions, and the analysis does not answer them.

The most useful probiotic evidence centers on B. lactis

The clearest elderly-specific protocol comes from Li et al.'s 2025 randomized, double-blind, placebo-controlled trial. The study randomized 67 adults aged 60 years or older who met Rome IV criteria for functional constipation. Participants took one post-dinner sachet daily for four weeks containing 2 × 10¹⁰ CFU of B. lactis BL-99 plus 0.8 g fructooligosaccharides (FOS), or placebo.

The primary outcome was spontaneous bowel-movement frequency. The trial also measured whole-gut transit time, constipation symptoms, the Patient Assessment of Constipation Symptoms score, and stool form. The BL-99/FOS group had a positive primary-endpoint result. The investigators also followed participants for two weeks after stopping the intervention, an unusual feature in probiotic trials that offers preliminary information about whether the effect immediately disappears. The study was small, single-site, and not designed to settle dose-response questions or identify which older adults benefit most.

Its result fits a wider, though still heterogeneous, pattern. Cheng et al.'s 2024 multicenter randomized trial tested B. lactis HN019 for eight weeks in adults with functional constipation at five hospitals. Doses ranged from 1.0 to 17.2 × 10⁹ CFU per day, and complete spontaneous bowel movements were the primary endpoint, a stricter outcome than spontaneous bowel movements alone. The trial reported positive constipation findings, extending the duration of evidence for this strain class to eight weeks.

A third trial of the MN-Gup variant of B. lactis reported constipation and gut-microbiota outcomes. In a separate elderly trial, Fehir Šola et al. found that a multistrain formulation containing Bifidobacterium, Lactobacillus, and Streptococcus improved stool frequency and consistency versus placebo.

These studies point in the same direction, but they are not interchangeable. They used different strains, formulations, doses, treatment lengths, populations, and primary outcomes. No head-to-head trial establishes that BL-99 beats HN019, that either beats MN-Gup, or that a single-strain product beats a multistrain product. "Contains probiotics" remains a product category, not a clinical prescription.

Microbiome changes are context, not proof of a mechanism

Constipation trials increasingly measure the microbiome alongside symptoms. Lai et al.'s 2023 double-blind, placebo-controlled trial examined dietary fiber and probiotic interventions in functional constipation and collected both symptom and gut-microbiota data. The study helps explain why fiber and probiotics might affect constipation through different changes in colonic microbial communities.

That is useful biological context, not proof that a particular microbial change caused a bowel-movement change. Similarly, Yang et al.'s 2023 multi-omics FMT study explored functional constipation in people with comorbid depression and anxiety and connected microbiome modulation with gut-brain signaling measures. It adds plausibility to the FMT literature, but it does not supply age- or frailty-stratified safety data.

Evidence also extends beyond functional constipation, with limits. A four-week double-blind trial in 180 people with constipation-predominant irritable bowel syndrome found that acacia fiber and a B. lactis supplement relieved gastrointestinal symptoms more than placebo. That IBS-C trial supports interest in the species, but IBS-C and chronic functional constipation are distinct diagnoses, and its results cannot be treated as an elderly-constipation result.

Why PEG still belongs in the conversation

A 2022 systematic review of constipation management in elderly patients supports osmotic laxatives such as PEG/macrogol as conventional first-line therapy. Their long clinical history and safety experience matter in a population often managing polypharmacy and comorbid disease. The same review advises caution with stimulant laxatives because adverse effects can matter more in older adults.

The probiotic case also has an unresolved aggregate-evidence problem. Li and colleagues note that prior meta-analytic evidence for synbiotics has not consistently shown improvement in constipation symptoms. One positive, 67-person trial should not erase that inconsistency. A 2022 Cochrane review in children likewise found insufficient evidence to support probiotics for pediatric functional constipation. Children are not older adults, but the review illustrates a recurring problem: probiotic trials often differ enough in strains and methods to make a single broad conclusion unreliable.

For an older adult with functional constipation, consider a defined B. lactis product for at least four weeks as an adjunct, particularly if the product identifies its strain and dose. The elderly BL-99/FOS trial used 2 × 10¹⁰ CFU plus 0.8 g FOS daily; adult HN019 evidence extends to eight weeks at 1.0–17.2 × 10⁹ CFU daily. Discuss changes to laxatives with the clinician managing the patient's medications.

The sensible conclusion is narrower than the hype. B. lactis has the most consistent strain-class signal among the probiotics described here, including direct evidence in older adults. PEG/macrogol remains the better-validated baseline treatment. FMT has an impressive comparative ranking but lacks the elderly safety evidence needed for routine use in this population. If constipation is new, severe, accompanied by bleeding, weight loss, anemia, vomiting, or major pain, the first intervention is medical evaluation—not a supplement.